Tet1 is required for Rb phosphorylation during G1/S phase transition

Biochemical and Biophysical Research Communications

Volumn 434, Issue 2, 2013, Pages 241-244

  Huang, Shengsong ^a   Zhu, Ziqi ^b   Wang, Yiqin ^b   Wang, Yanru ^b   Xu, Longxia ^b   Chen, Xuemei ^b   Xu, Qing ^b   Zhang, Qimin ^a   Zhao, Xin ^a   Yu, Yi ^b   Wu, Denglong ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Cyclin D1; G1 S phase entry; Hydroxylase; Rb phosphorylation; Tet1

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; HYBRID PROTEIN; MESSENGER RNA; PROTEIN P16; PROTEIN P27; PROTEIN TET1; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN 3T3; CELL SYNCHRONIZATION; DNA REPLICATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CYCLIN D1; DNA-BINDING PROTEINS; G1 PHASE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; LENTIVIRUS; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; S PHASE; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84877065903     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.110     Document Type: Article

References (31)

1. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398.
2. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
3. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
4. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
5. Das P.M., Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22:4632-4642.
6. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
7. Liao L.M., Brennan P., van Bemmel D.M., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., Navratilova M., Szeszenia-Dabrowska N., Mates D., Rothman N., Boffetta P., Chow W.H., Moore L.E. LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. PLoS ONE 2011, 6:e27361.
8. Bauerschlag D.O., Ammerpohl O., Brautigam K., Schem C., Lin Q., Weigel M.T., Hilpert F., Arnold N., Maass N., Meinhold-Heerlein I., Wagner W. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 2011, 80:12-20.
9. Campan M., Moffitt M., Houshdaran S., Shen H., Widschwendter M., Daxenbichler G., Long T., Marth C., Laird-Offringa I.A., Press M.F., Dubeau L., Siegmund K.D., Wu A.H., Groshen S., Chandavarkar U., Roman L.D., Berchuck A., Pearce C.L., Laird P.W. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS ONE 2011, 6:e28141.
10. Bhutani N., Burns D.M., Blau H.M. DNA demethylation dynamics. Cell 2011, 146:866-872.
11. Niehrs C. Active DNA demethylation and DNA repair. Differentiation 2009, 77:1-11.
12. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
13. Xu Y., Wu F., Tan L., Kong L., Xiong L., Deng J., Barbera A.J., Zheng L., Zhang H., Huang S., Min J., Nicholson T., Chen T., Xu G., Shi Y., Zhang K., Shi Y.G. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 2011, 42:451-464.
14. Wu H., D'Alessio A.C., Ito S., Xia K., Wang Z., Cui K., Zhao K., Sun Y.E., Zhang Y. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011, 473:389-393.
15. Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A., Rappsilber J., Helin K. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011, 473:343-348.
16. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
17. Ko M., Rao A. TET2: epigenetic safeguard for HSC. Blood 2011, 118:4501-4503.
18. Couronne L., Bastard C., Bernard O.A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 2012, 366:95-96.
19. Lemonnier F., Couronne L., Parrens M., Jais J.P., Travert M., Lamant L., Tournillac O., Rousset T., Fabiani B., Cairns R.A., Mak T., Bastard C., Bernard O.A., de Leval L., Gaulard P. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012, 120:1466-1469.
20. Perez C., Martinez-Calle N., Martin-Subero J.I., Segura V., Delabesse E., Fernandez-Mercado M., Garate L., Alvarez S., Rifon J., Varea S., Boultwood J., Wainscoat J.S., Cruz Cigudosa J., Calasanz M.J., Cross N.C., Prosper F., Agirre X. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS ONE 2012, 7:e31605.
21. Pronier E., Delhommeau F. Role of TET2 mutations in myeloproliferative neoplasms. Curr. Hematol. Malig. Rep. 2012, 7:57-64.
22. Weissmann S., Alpermann T., Grossmann V., Kowarsch A., Nadarajah N., Eder C., Dicker F., Fasan A., Haferlach C., Haferlach T., Kern W., Schnittger S., Kohlmann A. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012, 26:934-942.
23. Yamazaki J., Taby R., Vasanthakumar A., Macrae T., Ostler K.R., Shen L., Kantarjian H.M., Estecio M.R., Jelinek J., Godley L.A., Issa J.P. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012, 7:201-207.
24. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002, 62:4075-4080.
25. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
26. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., Carpenter A.E., Foo S.Y., Stewart S.A., Stockwell B.R., Hacohen N., Hahn W.C., Lander E.S., Sabatini D.M., Root D.E. A lentiviralRNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
27. Donjerkovic D., Scott D.W. Regulation of the G1 phase of the mammalian cell cycle. Cell Res. 2000, 10:1-16.
28. Deshpande A., Sicinski P., Hinds P.W. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005, 24:2909-2915.
29. Lian C.G., Xu Y., Ceol C., Wu F., Larson A., Dresser K., Xu W., Tan L., Hu Y., Zhan Q., Lee C.W., Hu D., Lian B.Q., Kleffel S., Yang Y., Neiswender J., Khorasani A.J., Fang R., Lezcano C., Duncan L.M., Scolyer R.A., Thompson J.F., Kakavand H., Houvras Y., Zon L.I., Mihm M.C., Kaiser U.B., Schatton T., Woda B.A., Murphy G.F., Shi Y.G. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146.
30. Miura T., Mattson M.P., Rao M.S. Cellular lifespan and senescence signaling in embryonic stem cells. Aging Cell 2004, 3:333-343.
31. Dawlaty M.M., Ganz K., Powell B.E., Hu Y.C., Markoulaki S., Cheng A.W., Gao Q., Kim J., Choi S.W., Page D.C., Jaenisch R. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9:166-175.